Ergoteles LLC Iovance Biotherapeutics, Inc. Transaction History

Ergoteles LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	BUY	$5.53 - $8.22 $147,977 - $219,958	26,759 Added 19.19%	166,172 $1.02 Million
Q4 2022 Feb 14, 2023	BUY	$5.62 - $10.0 $529,831 - $942,760	94,276 Added 208.87%	139,413 $890,000
Q3 2022 Nov 14, 2022	BUY	$9.53 - $13.11 $430,155 - $591,746	45,137 New	45,137 $432,000
Q2 2022 Aug 12, 2022	SELL	$6.38 - $18.33 $798,961 - $2.3 Million	-125,229 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$12.38 - $19.1 $132,404 - $204,274	10,695 Added 9.34%	125,229 $2.09 Million
Q4 2021 Feb 14, 2022	BUY	$16.55 - $27.63 $44,685 - $74,601	2,700 Added 2.41%	114,534 $2.19 Million
Q3 2021 Nov 15, 2021	BUY	$20.35 - $26.63 $1.34 Million - $1.76 Million	65,966 Added 143.82%	111,834 $2.76 Million
Q2 2021 Aug 12, 2021	SELL	$16.33 - $33.07 $2.5 Million - $5.07 Million	-153,379 Reduced 76.98%	45,868 $1.19 Million
Q1 2021 May 12, 2021	BUY	$28.67 - $52.59 $2.74 Million - $5.03 Million	95,578 Added 92.2%	199,247 $6.31 Million
Q4 2020 Feb 11, 2021	BUY	$28.04 - $50.26 $1.13 Million - $2.03 Million	40,317 Added 63.64%	103,669 $4.81 Million
Q3 2020 Nov 16, 2020	BUY	$27.75 - $36.3 $1.76 Million - $2.3 Million	63,352 New	63,352 $2.09 Million

314

241M

3.77M

1.7M

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $1.24B
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

Stay updated on Ergoteles LLC with notifications on news.